Our data further show that MLLr-B-ALL blasts mobilized to PB with NG2 antagonists do in fact become sensitized to conventional chemotherapy (VxL) as demonstrated by lower levels of MRD and therefore higher rates of CR at treatment completion, resulting in higher EFS and delayed time to relapse. Here, CSPG4 is linked to acute lymphoblastic leukemia.